Apimeds Pharmaceuticals US, Inc
APUS
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.86M
Close$
$-5.63
307.7% downside
Current Fair Value
307.7% downsideOvervalued by 307.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.86 Million |
|---|---|
| Enterprise Value | $20.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.5 |
| Beta | 0.15 |
| Outstanding Shares | 1,632,818 |
Return
| Return on Equity | -54.65% |
|---|---|
| Return on Assets | -45.58% |
| Return on Invested Capital | -25.67% |
Valuation & Multiples
| P/E Ratio | -0.08 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | 0.04 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.74 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.72 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.89%▲ 2.53% |
|---|---|
| Total Invested | $802,954▲ 23.73% |
| Investors Holding | 6▼ 1.00% |
ESG Score
No data
About Apimeds Pharmaceuticals US, Inc
2 employees
CEO: Erik C. Emerson Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment ...